All AbMole products are for research use only, cannot be used for human consumption.
CAY10603 (BML-281) prevents the growth of several pancreatic cancer cell lines (IC50 = 0.1-1 μM). CAY10603 (BML-281) shows potent antiproliferative activity against pancreatic cancer cell lines with IC50 of <1 μM. CAY10603 can be used as a new molecular probe in exploring HDAC biology.
| Cell Experiment | |
|---|---|
| Cell lines | BxPc-3, HupT3, Mia Paca-2, Panc 04.03, and SU 86.86 cells |
| Preparation method | Growing the pancreatic cancer cell lines BxPc-3, HupT3, Mia Paca-2, Panc 04.03, and SU 86.86 in medium (DMEM or RPMI) which contains 10% fetal calf serum and l-glutamine. Plating pancreatic cancer cells out in duplicate into 6 wells of a 96-well microtiter plate. Four hours post plating, treting individual wells with diluent (DMSO) or varying concentrations of SAHA or the indicated HDACIs from a concentration of 1 nM to 50 mM.Measuring cytotoxicity at time “0”, and 72 h post treatment using the colorimetric MTT assay according to the manufacturer’s suggestions. Using XLfit to calculate the IC50 values . |
| Concentrations | ~50 μM |
| Incubation time | 72 hours |
| Animal Experiment | |
|---|---|
| Animal models | |
| Formulation | |
| Dosages | |
| Administration | |
| Molecular Weight | 446.5 |
| Formula | C22H30N4O6 |
| CAS Number | 1045792-66-2 |
| Solubility (25°C) | DMSO ≥ 50 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related HDAC Products |
|---|
| CM-444
CM-444 is an inhibitor for HDAC and DNA methyltransferases (DNMT) with IC50 values of 6 nM-0.6 μM and 1.8-2.3 μM, respectively. CM-444 is an inducer for the differentiation of acute myeloid leukemia cells. CM-444 exhibits anti-leukemic activity and improves the survival rate in mouse models. |
| CM-1758
CM-1758 is a histone deacetylase (HDAC) inhibitor. CM-1758 inhibits tumor growth in vivo. CM-1758 induces acetylation of non-histone proteins in acute myeloid leukemia cells. |
| T-518
T-518 is an orally active, selective, and blood-brain barrier permeable HDAC6 inhibitor with an IC50 value of 36 nM for human HDAC6. |
| SE-7552
SE-7552, a 2-(difluoromethyl)-1,3,4-oxadiazole (DFMO) derivative, is an orally active, highly selective, non-hydroxamate HDAC6 inhibitor with an IC50 of 33 nM. |
| BRD9757
BRD9757 is a potent, capless and selective HDAC6 inhibitor with an IC50 of 30 nM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
